Results 181 to 190 of about 823,777 (226)

Targeted protein degradation dismantles undruggable targets to reverse immune evasion and therapy resistance in cancer. [PDF]

Front Immunol
Zhang F, Wang Q, Li M, Wang T, Lei P, Huang T, Wu Z.   +6 more
europepmc   +1 more source

4-2 VHL-Recruiting PROTAC Inhibits the Growth and Migration of Triple Negative Breast Cancer Cells by Triggering Pyroptosis Through Fas-Mediated IL-17 Signaling. [PDF]

Drug Dev Res
Wang Q, Huang Q, Ou H, Huang T, He Y, Li P.   +5 more
europepmc   +1 more source

AI-Driven Multi-Omics Integration of Synthetic Colon Adenocarcinoma for Cluster-Guided PROTAC Candidate Design Targeting KRASG12D. [PDF]

Int J Mol Sci
Elamin KM, Elbashir SMI, Adam I.
europepmc   +1 more source

Pocket-PROTACs: an interpretable pocket-aware deep learning framework for predicting PROTAC-induced protein degradation. [PDF]

Bioinformatics
Chen K, Huang Z, Wang Y, Shen S, Song J, Deng L.   +5 more
europepmc   +1 more source

Targeting Bruton's Tyrosine Kinase in CLL: Selectivity, Resistance Mechanisms, and Emerging Therapeutic Strategies. [PDF]

Cells
Bravo E, Pastrana CC, Lamkin EN, Ciurko K, Taylor J.   +4 more
europepmc   +1 more source

Proteolysis‑targeting chimeras in oral squamous cell carcinoma: Current evidence, translational challenges and future directions (Review). [PDF]

Mol Med Rep
Bai Y, Ma D, Yang X, Wang M.
europepmc   +1 more source

Clinical Breakthrough in Targeted Protein Degradation: Reflections on the Approval of ARV-471. [PDF]

Cancer Innov
Rao Y.
europepmc   +1 more source

Targeted Protein Degradation Strategies in DNA Virus Research. [PDF]

Viruses
Lam M, Hill C, Thornburg E, DeSmet M.
europepmc   +1 more source

Dual PROTACs Versus Dual Inhibitors in Oncology: A Medicinal Chemistry and Linker Design Perspective. [PDF]

Pharmaceuticals (Basel)
Bisi N, Hamze A.
europepmc   +1 more source

Vepdegestrant for ESR1-mutated breast cancer. [PDF]

Trends Pharmacol Sci
MacLeod RS, Liu CJ.
europepmc   +1 more source